European committee backs subcutaneous formulation of Bristol Myers’ Opdivo

Investing.com -- Bristol Myers (NYSE: BMY ) Squibb announced on Friday that a key European regulatory committee has endorsed a subcutaneous formulation of its blockbuster cancer drug, Opdivo.

The Committee for Medicinal Products for Human Use (CHMP), a part of the European Medicines Agency, recommended the approval of this formulation for use in multiple previously approved adult solid tumors.

The recommended applications include its use as a monotherapy, as monotherapy maintenance following the completion of combination therapy with Opdivo and Yervoy, or in combination with chemotherapy or cabozantinib.

The Princeton, New Jersey-based biopharmaceutical company also stated that the European Commission, which typically adheres to the advice of the CHMP, will now review the recommendation. A decision from the European Commission is anticipated by June 2.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.